FlexShopper is undergoing a capital structure transformation, aiming to repurchase preferred stock at a discount through a ...

Direct Line's recent operating performance has improved, showing progress in its turnaround program, despite past weak trends ...

Adaptive Biotechnologies posted strong Q3 results, beating expectations and reducing losses, while management has done a good ...

Axsome Therapeutics (NASDAQ:AXSM) said a long-term Phase 3 study of its drug AXS-12 for the treatment of narcolepsy with cataplexy has met its primary endpoint. The study showed AXS-12 was able to ...